Minerva Neurosciences Swings to Q3 Net Income of $100.7 Million

Bitget2026/11/06 14:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Minerva Neurosciences swung to third-quarter 2026 GAAP net income of $100.7 million from a year-earlier loss.
A $109.6 million non-cash gain from changes in the warrant liability’s fair value drove the quarterly profit.
Quarterly research and development expenses rose to $5.2 million, while general and administrative expenses increased to $4.3 million year over year.
The ongoing confirmatory Phase 3 roluperidone trial remains on track for topline efficacy data in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060900OMX_____CNEWS_EN_GNW9872144_en) on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Minerva Neurosciences Swings to Q3 Net Income of $100.7 Million

You may also like

Crypto prices